Literature DB >> 8887297

Carbamylated hemoglobin: a potential marker for the adequacy of hemodialysis therapy in end-stage renal failure.

A Davenport1, S Jones, S Goel, J P Astley, T G Feest.   

Abstract

Urea can dissociate in vivo to form isocyanic acid which can react with hemoglobin to form carbamylated hemoglobin. Previous work has shown that formation of carbamylated hemoglobin depends upon both the severity and the duration of renal failure. To determine whether carbamylated hemoglobin can be used as an assessment of the adequacy of hemodialysis treatment, we prospectively studied 55 stable patients who regularly attended our hospital dialysis program. Carbamylated hemoglobin was greater in those patients with a Kt/V of < or = 1.1 compared to those with a Kt/V of > 1.1 (120 +/- 8 micrograms VH/gHb versus 99 +/- 7, P < 0.01), and there was a negative correlation with Kt/V (r = -0.37, P = 0.007). There were positive correlations between carbamylated hemoglobin and the time-averaged urea concentration (r = 0.4, P = 0.004), and a negative correlation with the urea reduction ratio (r = -0.37, P = 0.01). Carbamylated hemoglobin may therefore be a useful marker of the degree of uremia, just as glycosylated hemoglobin is used in the assessment of patients with diabetes mellitus.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8887297     DOI: 10.1038/ki.1996.447

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  9 in total

Review 1.  Urea and atherosclerosis--evidence for a direct link involving apolipoprotein B protein modifications.

Authors:  Christian Albert; Peter R Mertens; Peter Bartsch
Journal:  Int Urol Nephrol       Date:  2011-05-19       Impact factor: 2.370

Review 2.  Mechanisms and consequences of carbamoylation.

Authors:  Sigurd Delanghe; Joris R Delanghe; Reinhart Speeckaert; Wim Van Biesen; Marijn M Speeckaert
Journal:  Nat Rev Nephrol       Date:  2017-07-31       Impact factor: 28.314

Review 3.  The diagnosis of posttransplantation diabetes mellitus: meeting the challenges.

Authors:  J Werzowa; M Hecking; M Haidinger; D Döller; A Sharif; A Tura; M D Säemann
Journal:  Curr Diab Rep       Date:  2015-05       Impact factor: 4.810

Review 4.  Protein carbamylation in end stage renal disease: is there a mortality effect?

Authors:  Sahir Kalim
Journal:  Curr Opin Nephrol Hypertens       Date:  2018-11       Impact factor: 2.894

5.  Measurement of Hba(1C) in patients with chronic renal failure.

Authors:  Randie R Little; Curt L Rohlfing; Alethea L Tennill; Steven E Hanson; Shawn Connolly; Trefor Higgins; Charles E Wiedmeyer; Cas W Weykamp; Richard Krause; William Roberts
Journal:  Clin Chim Acta       Date:  2013-01-12       Impact factor: 3.786

6.  Evaluation of retinol binding protein 4 and carbamoylated haemoglobin as potential renal toxicity biomarkers in adult mice treated with (177)Lu-octreotate.

Authors:  Johanna Dalmo; Emelie Westberg; Lars Barregard; Lisa Svedbom; Martin Johansson; Margareta Törnqvist; Eva Forssell-Aronsson
Journal:  EJNMMI Res       Date:  2014-10-31       Impact factor: 3.138

Review 7.  Carbamylated Proteins in Renal Disease: Aggravating Factors or Just Biomarkers?

Authors:  Laëtitia Gorisse; Stéphane Jaisson; Christine Piétrement; Philippe Gillery
Journal:  Int J Mol Sci       Date:  2022-01-05       Impact factor: 5.923

Review 8.  Protein carbamylation in kidney disease: pathogenesis and clinical implications.

Authors:  Sahir Kalim; S Ananth Karumanchi; Ravi I Thadhani; Anders H Berg
Journal:  Am J Kidney Dis       Date:  2014-07-16       Impact factor: 8.860

9.  Evalution of in vitro effect of flavonoids on human low-density lipoprotein carbamylation.

Authors:  Mohammad Ali Ghaffari; Mehrnoosh Shanaki
Journal:  Iran J Pharm Res       Date:  2010       Impact factor: 1.696

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.